The TNFα-transgenic rat: Hippocampal synaptic integrity, cognition, function, and post-ischemic cell loss

PLoS ONE

Volumn 11, Issue 5, 2016, Pages

  Pettigrew, L Creed ^a,b,c   Kryscio, Richard J ^b,d   Norris, Christopher M ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c LEXINGTON VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF KENTUCKY COLLEGE OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR;

ANIMAL; CEREBRAL ARTERY DISEASE; COGNITION; GENETICS; HIPPOCAMPUS; LONG TERM POTENTIATION; NERVE CELL; NERVE CELL PLASTICITY; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; SYNAPTIC TRANSMISSION; TRANSGENIC RAT;

ANIMALS; COGNITION; HIPPOCAMPUS; INFARCTION, MIDDLE CEREBRAL ARTERY; LONG-TERM POTENTIATION; NEURONAL PLASTICITY; NEURONS; RATS; RATS, TRANSGENIC; SYNAPTIC TRANSMISSION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85009983223     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0154721     Document Type: Article

References (87)

1. Emsley HC, Tyrrell PJ. (2002) Inflammation and infection in clinical stroke. J Cereb Blood Flow Metab. 22: 1399–419. PMID: 12468886
2. Mayne M, Ni W, Yan HJ, Xue M, Johnston JB, Del Bigio MR, et al. (2001) Antisense oligodeoxynucleotide inhibition of tumor necrosis factor-alpha expression is neuroprotective after intracerebral hemorrhage. Stroke. 32: 240–8. PMID: 11136943
3. Tomimoto H, Ihara M, Wakita H, Ohtani R, Lin JX, Akiguchi I, et al. (2003) Chronic cerebral hypoperfusion induces white matter lesions and loss of oligodendroglia with DNA fragmentation in the rat. Acta Neuropathol. 106: 527–34. PMID: 13680276
4. Lotocki G, Alonso OF, Dietrich WD, Keane RW. (2004)Tumor necrosis factor receptor 1 and its signaling intermediates are recruited to lipid rafts in the traumatized brain. J Neurosci. 24: 11010–6. PMID: 15590916.
5. Tomimoto H, Akiguchi I, Wakita H, Kinoshita A, Ikemoto A, Nakamura S, et al. (1996) Glial expression of cytokines in the brains of cerebrovascular disease patients. Acta Neuropathol. 92: 281–7. PMID: 8870830.
6. Sairanen T, Carpén O, Karjalainen-Lindsberg ML, Paetau A, Turpeinen U, Kaste M, et al. (2001) Evolution of cerebral tumor necrosis factor-alpha production during human ischemic stroke. Stroke. 32: 1750–8. PMID: 11486101
7. Carlstedt F, Lind L, Lindahl B. (1997) Proinflammatory cytokines, measured in a mixed population on arrival in the emergency department, are related to mortality and severity of disease. J Intern Med. 242: 361–5. PMID: 9408063
8. Vila N, Castillo J, Davalos A, Chamorro A. (2000) Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke. 31: 2325–9. PMID: 11022058
9. Zaremba J, Skrobanski P, Losy J. (2001) Tumor necrosis factor-alpha is increased in the cerebrospinal fluid and serum of ischaemic stroke patients and correlates with the volume of evolving brain infarct. Biomed Pharmacother. 55: 258–63. PMID: 11428551
10. Sairanen TR, Lindsberg PJ, Brenner M, Carpén O, Sirén AL. (2001) Differential cellular expression of tumor necrosis factor-α and Type I tumor necrosis factor receptor after transient global forebrain ischemia. J Neurol Sci. 186: 87–99. PMID: 11412877
11. Saito K, Suyama K, Nishida K, Sei Y, Basile AS. (1996) Early increases in TNF-α, IL-6, and IL-1β levels following transient cerebral ischemia in gerbil brain. Neurosci Lett. 206: 149–52. PMID: 8710173
12. Liu Y, Jacobowitz DM, Barone F, McCarron R, Spatz M, Feuerstein G, et al. (1994) Quantitation of perivascular monocytes and macrophages around cerebral blood vessels of hypertensive and aged rats. J Cereb Blood Flow Metab. 14: 348–52. PMID: 8113330
13. Barone FC, Arvin B, White RF, Miller A, Webb CL, Willette RN, et al. (1997) Tumor necrosis factor-alpha: a mediator of focal ischemic brain injury. Stroke. 28: 1233–44. PMID: 9183357
14. Dawson DA, Martin D, Hallenbeck JM. (1996) Inhibition of tumor necrosis factor-alpha reduces focal cerebral ischemic injury in the spontaneously hypertensive rat. Neurosci Lett. 218: 41–4. PMID: 8939476
15. Nawashiro H, Martin D, Hallenbeck JM. (1997) Inhibition of tumor necrosis factor and amelioration of brain infarction in mice. J Cereb Blood Flow Metab. 17: 229–32. PMID: 9040503
16. Nawashiro H, Tasaki K, Ruetzler CA, Hallenbeck JM. (1997) TNF-alpha pretreatment induces protective effects against focal cerebral ischemia in mice. J Cereb Blood Flow Metab. 17: 483–90. PMID: 9183285
17. Lavine SD, Hofman FM, Zlokovic BV. (1998) Circulating antibody against tumor necrosis factor-alpha protects rat brain from reperfusion injury. J Cereb Blood Flow Metab. 18: 52–8. PMID: 9428305
18. Yang GY, Gong C, Qin Z, Ye W, Mao Y, Bertz AL. (1998) Inhibition of TNF-α attenuates infarct volume and ICAM-1 expression in ischemic mouse brain. Neuroreport. 9: 2131–4. PMID: 9674607
19. Marchetti L, Klein M, Schlett K, Pfizenmaier K, Eisel UL. (2004) Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pathway. J Biol Chem. 279: 32869–81. PMID: 15155767
20. Wajant H, Pfizenmaier K, Scheurich P. (2003) Tumor necrosis factor signaling. Cell Death Differ. 10: 45–65. PMID: 12655295
21. Iosif RE, Ekdahl CT, Ahlenius H, Pronk CJ, Bonde S, Kokaia Z, et al. (2006) Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis. J Neurosci. 26: 9703–12. PMID: 16988041
22. Iosif RE, Ahlenius H, Ekdahl CT, Darsalia V, Thored P, Jovinge S, et al. (2008) Suppression of stroke-induced progenitor proliferation in adult subventricular zone by tumor necrosis factor receptor 1. J Cereb Blood Flow Metab. 28: 1574–87. PMID: 18493257 doi: 10.1038/jcbfm.2008.47
23. Beattie EC, Stellwagen D, Morishita W, Bresnahan JC, Ha BK, Von Zastrow M, et al. (2002) Control of synaptic strength by glial TNFalpha. Science. 295: 2282–5. PMID: 11910117
24. Stellwagen D, Malenka RC. (2006) Synaptic scaling mediated by glial TNF-alpha. Nature. 440: 1054–9. PMID: 16547515
25. Stellwagen D, Beattie EC, Seo JY, Malenka RC. (2005) Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J Neurosci. 25: 3219–28. PMID: 15788779
26. Golan H, Levav T, Mendelsohn A, Huleihel M. (2004) Involvement of tumor necrosis factor alpha in hippocampal development and function. Cereb Cortex. 14: 97–105. PMID: 14654461
27. Tancredi V, D'Arcangelo G, Grassi F, Tarroni P, Palmieri G, Santoni G, et al. (1992) Tumor necrosis factor alters synaptic transmission in rat hippocampal slices. Neurosci Lett. 146: 176–8. PMID: 1337194
28. Cunningham AJ, Murray CA, O'Neill LA, Lynch MA, O'Conner JJ. (1996) Interleukin-1 beta (IL-1 beta) and tumour necrosis factor (TNF) inhibit long-term potentiation in the rat dentate gyrus in vitro. Neurosci Lett. 203: 17–20. PMID: 8742036
29. Butler MP, O'Connor JJ, Moynagh PN. (2004) Dissection of tumor-necrosis factor-alpha inhibition of long-term potentiation (LTP) reveals a p38 mitogen-activated protein kinase-dependent mechanism which maps to early-but not late-phase LTP. Neuroscience. 124: 319–26. PMID: 14980382
30. Bliss TV, Collingridge GL. (1993) A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 361: 31–9. PMID: 8421494
31. Butler MP, Moynagh PN, O'Connor JJ. (2002) Methods of detection of the transcription factor NF-kappa B in rat hippocampal slices. J Neurosci Methods. 119: 185–90. PMID: 12323422
32. Albensi BC, Mattson MP. (2000) Evidence for the involvement of TNF and NF-κB in hippocampal synaptic plasticity. Synapse. 35: 151–9. PMID: 10611641
33. Pettigrew LC, Kindy MS, Scheff S, Springer JE, Kryscio RJ, Li Y, et al. (2008) Focal cerebral ischemia in the TNFalpha-transgenic rat. J Neuroinflammation. 5: 47. doi: 10.1186/1742-2094-5-47 PMID: 18947406
34. Sama DM, Mohmmad Abdul H, Furman JL, Artiushin IA, Szymkowski DE, Scheff SW, et al. (2012) Inhibition of soluble tumor necrosis factor ameliorates synaptic alterations and Ca2+ dysregulation in aged rats. PLoS One. 7(5):e38170. doi: 10.1371/journal.pone.0038170 PMID: 22666474
35. Furman JL, Sama DM, Gant JC, Beckett TL, Murphy MP, Bachstetter AD, et al. (2012) Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease. J Neurosci. 32: 16129–40. PMID: 23152597 doi: 10.1523/JNEUROSCI.2323-12.2012
36. Furman JL, Sompol P, Kraner SD, Pleiss MM, Putman EJ, Dunkerson J, et al. (2016) Blockade of Astrocytic Calcineurin/NFAT Signaling Helps to Normalize Hippocampal Synaptic Function and Plasticity in a Rat Model of Traumatic Brain Injury. J Neurosci. 36: 1502–15. PMID: 26843634 doi: 10.1523/ JNEUROSCI.1930-15.2016
37. Norris CM, Sompol P, Roberts KN, Ansari M, Scheff SW. (2016) Pycnogenol protects CA3-CA1 synaptic function in a rat model of traumatic brain injury. Exp Neurol. 276: 5–12. PMID: 26607913 doi: 10. 1016/j.expneurol.2015.11.006
38. Mathis DM, Furman JL, Norris CM. (2011) Preparation of acute hippocampal slices from rats and transgenic mice for the study of synaptic alterations during aging and amyloid pathology. J Vis Exp. 2011 (49). doi: 10.3791/2330 PMID: 21490565
39. Zea Longa E, Weinstein PR, Carlson S, Cummins R. (1989) Reversible middle cerebral artery occlusion without craniotomy in rats. Stroke. 20:84–91. PMID: 2643202
40. Dubal DB, Kashon ML, Pettigrew LC, Ren JM, Finklestein SP, Rau SW, et al. (1998) Estradiol protects against ischemic injury. J Cereb Blood Flow Metab. 18: 1253–8. PMID: 9809515
41. Belayev L, Alonso OF, Busto R, Zhao W, Ginsberg MD. (1996) Middle cerebral artery occlusion in the rat by intraluminal suture. Neurological and pathological evaluation of an improved model. Stroke. 27: 1616–23. PMID: 8784138
42. Foster TC, Sharrow KM, Kumar A, Masse J. (2003) Interaction of age and chronic estradiol replacement on memory and markers of brain aging. Neurobiol Aging. 24: 839–52. PMID: 12927766
43. Foster TC, Sharrow KM, Masse JR, Norris CM, Kumar A. (2001) Calcineurin links Ca2+ dysregulation with brain aging. J Neurosci. 21:4066–73. PMID: 11356894
44. Norris CM, Foster TC. (1999) MK-801 improves retention in aged rats: implications for altered neural plasticity in age-related memory deficits. Neurobiol Learn Mem. 71: 194–206. PMID: 10082639
45. Candelario-Jalil E, Mhadu NH, Gonzalez-Falcon A, Garcia-Cabrera M, Munoz E, Leon OS, et al. (2005) Effects of the cyclooxygenase-2 inhibitor nimesulide on cerebral infarction and neurological deficits induced by permanent middle cerebral artery occlusion in the rat. J Neuroinflammation. 2(1): 3. PMID: 15656909
46. Yulug B, Kilic U, Kilic E, Bahr M. (2004) Rifampicin attenuates brain damage in focal ischemia. Brain Res. 996: 76–80. PMID: 14670633
47. Hellmich HL, Capra B, Eidson K, Garcia J, Kennedy D, Uchida T, et al. (2005) Dose-dependent neuronal injury after traumatic brain injury. Brain Res. 1044: 144–54. PMID: 15885213
48. Tejadilla D, Cerbon M, Morales T. (2010) Prolactin reduces the damaging effects of excitotoxicity in the dorsal hippocampus of the female rat independently of ovarian hormones. Neuroscience. 169: 1178–85. PMID: 20570717 doi: 10.1016/j.neuroscience.2010.05.074
49. de la Tremblaye PB, Plamondon H. (2011) Impaired conditioned emotional response and object recognition are concomitant to neuronal damage in the amygdala and perirhinal cortex in middle-aged ischemic rats. Behav Brain Res. 219: 227–33. PMID: 21238489 doi: 10.1016/j.bbr.2011.01.009
50. Norris CM, Scheff SW. (2009) Recovery of afferent function and synaptic strength in hippocampal CA1 following traumatic brain injury. J Neurotrauma. 26: 2269–78. PMID: 19604098 doi: 10.1089/neu.2009. 1029
51. Furman JL, Sama DM, Gant JC, Beckett TL, Murphy MP, Bachstetter AD, et al. (2012) Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease. J Neurosci. 32: 16129–40. PMID: 23152597 doi: 10.1523/JNEUROSCI.2323-12.2012
52. Dumas TC. (2012) Postnatal alterations in induction threshold and expression magnitude of long-term potentiation and long-term depression at hippocampal synapses. Hippocampus. 22: 188–99. PMID: 21069779 doi: 10.1002/hipo.20881
53. Dumas TC, Foster TC. (1995) Developmental increase in CA3-CA1 presynaptic function in the hippocampal slice. J Neurophysiol. 73: 1821–8. PMID: 7623083
54. Dumas TC. (2005) Late postnatal maturation of excitatory synaptic transmission permits adult-like expression of hippocampal-dependent behaviors. Hippocampus. 15: 562–78. PMID: 15884034
55. Rudy JW, Stadler-Morris S, Albert P. (1987) Ontogeny of spatial navigation behaviors in the rat: dissociation of "proximal"- and "distal"-cue-based behaviors. Behav Neurosci. 101: 62–73. PMID: 3828056
56. Wall AM, Mukandala G, Greig NH, O'Connor JJ. (2015) Tumor necrosis factor-alpha potentiates long-term potentiation in the rat dentate gyrus after acute hypoxia. J Neurosci Res. 93: 815–29. PMID: 25641742 doi: 10.1002/jnr.23540
57. Aloe L, Properzi F, Probert L, Akassoglou K, Kassiotis G, Micera A, et al. (1999) Learning abilities, NGF and BDNF brain levels in two lines of TNF-α transgenic mice, one characterized by neurological disorders, the other phenotypically normal. Brain Res. 840: 125–37 PMID: 10517960
58. Greco A, De Virgilio A, Gallo A, Fusconi M, Ruoppolo G, Turchetta R, et al. (2014) Idiopathic bilateral vestibulopathy: an autoimmune disease? Autoimmun Rev. 13: 1042–7. PMID: 25173622 doi: 10.1016/ j.autrev.2014.08.035
59. Arbusow V, Strupp M, Dieterich M, Stocker W, Naumann A, Schulz P, et al. (1998) Serum antibodies against membranous labyrinth in patients with "idiopathic" bilateral vestibulopathy. J Neurol. 245: 132–6. PMID: 9553841
60. Merrill JE, Graves MC, Mulder DG. (1992) Autoimmune disease and the nervous system. Biochemical, molecular, and clinical update. West J Med. 156: 639–46. PMID: 1319627
61. Solomon AJ, Spain RI, Kruer MC, Bourdette D. (2011) Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors. Mult Scler. 17:1472–87. PMID: 21816758 doi: 10. 1177/1352458511412996
62. De Paepe B, Creus KK, De Bleecker JL. (2012) The tumor necrosis factor superfamily of cytokines in the inflammatory myopathies: potential targets for therapy. Clin Dev Immunol. 2012:369432. doi: 10. 1155/2012/369432 PMID: 22110532
63. Hallenbeck JM. (2002) The many faces of tumor necrosis factor in stroke. Nat Med. 8: 1363–8. PMID: 12457181
64. Ruetzler CA, Furuya K, Takeda H, Hallenbeck JM. (2001) Brain vessels normally undergo cyclic activation and inactivation: evidence from tumor necrosis factor-alpha, heme oxygenase-1, and manganese superoxide dismutase immunostaining of vessels and perivascular brain cells. J Cereb Blood Flow Metab. 21: 244–52. PMID: 11295879
65. Wakita H, Ruetzler C, Illoh KO, Chen Y, Takanohashi A, Spatz M, et al. (2008) Mucosal tolerization to E-selectin protects against memory dysfunction and white matter damage in a vascular cognitive impairment model. J Cereb Blood Flow Metab. 28: 341–53. PMID: 17637705
66. Takeda H, Spatz M, Ruetzler C, McCarron R, Becker K, Hallenbeck J. (2002) Induction of mucosal tolerance to E-selectin prevents ischemic and hemorrhagic stroke in spontaneously hypertensive genetically stroke-prone rats. Stroke. 33: 2156–63. PMID: 12215580
67. Chen Y, Ruetzler C, Pandipati S, Spatz M, McCarron RM, Becker K, et al. (2003) Mucosal tolerance to E-selectin provides cell-mediated protection against ischemic brain injury. Proc Natl Acad Sci U S A. 100:15107–12. PMID: 14645708
68. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, et al. (1995) The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. 83: 793–802. PMID: 8521496
69. Grell M, Wajant H, Zimmermann G, Scheurich P. (1998) The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci U S A. 95: 570–5. PMID: 9435233
70. McCoy MK, Tansey MG. (2008) TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation. 5:45. doi: 10.1186/1742-2094-5-45 PMID: 18925972
71. Steed PM, Tansey MG, Zalevsky J, Zhukovsky EA, Desjarlais JR, Szymkowski DE, et al. (2003) Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science. 301: 1895–8. PMID: 14512626
72. McCoy MK, Martinez TN, Ruhn KA, Szymkowski DE, Smith CG, Botterman BR, et al. (2006) Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J Neurosci. 26: 9365–75. PMID: 16971520
73. Barnum CJ, Chen X, Chung J, Chang J, Williams M, Grigoryan N, et al. (2014) Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro(R)1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats. J Parkinsons Dis. 4: 349–60. PMID: 25061061 doi: 10.3233/JPD-140410
74. McAlpine FE, Lee JK, Harms AS, Ruhn KA, Blurton-Jones M, Hong J, et al. (2009) Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis. 34: 163–77. PMID: 19320056
75. Brambilla R, Ashbaugh JJ, Magliozzi R, Dellarole A, Karmally S, Szymkowski DE, et al. (2011) Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination. Brain. 134: 2736–54. PMID: 21908877 doi: 10.1093/ brain/awr199
76. Probert L, Akassoglou K, Pasparakis M, Kontogeorgos G, Kollias G. (1995) Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc Natl Acad Sci U S A. 92: 11294–8. PMID: 7479982
77. Probert L, Akassoglou K, Alexopoulou L, Douni E, Haralambous S, Hill S, et al. (1996) Dissection of the pathologies induced by transmembrane and wild-type tumor necrosis factor in transgenic mice. J Leukoc Biol. 59: 518–25. PMID: 8613699
78. Katsuki H, Nakai S, Hirai Y, Akaji K, Kiso Y, Satoh M. (1990) Interleukin-1 beta inhibits long-term potentiation in the CA3 region of mouse hippocampal slices. Eur J Pharmacol. 181: 323–6. PMID: 2166677
79. Bellinger FP, Madamba S, Siggins GR. (1993) Interleukin 1 beta inhibits synaptic strength and long-term potentiation in the rat CA1 hippocampus. Brain Res. 628: 227–34. PMID: 8313151
80. D'Arcangelo G, Grassi F, Ragozzino D, Santoni A, Tancredi V, Eusebi F. (1991) Interferon inhibits synaptic potentiation in rat hippocampus. Brain Res. 564: 245–8. PMID: 1725767
81. Bellinger FP, Madamba SG, Campbell IL, Siggins GR. (1995) Reduced long-term potentiation in the dentate gyrus of transgenic mice with cerebral overexpression of interleukin-6. Neurosci Lett. 198: 95–8. PMID: 8592650
82. Sama DM, Norris CM. (2013) Calcium dysregulation and neuroinflammation: discrete and integrated mechanisms for age-related synaptic dysfunction. Ageing Res Rev. 12: 982–95. PMID: 23751484 doi: 10.1016/j.arr.2013.05.008
83. Knapp LT, Klann E. (2002) Role of reactive oxygen species in hippocampal long-term potentiation: contributory or inhibitory? J Neurosci Res. 70: 1–7. PMID: 12237859
84. Serrano F, Klann E. (2004) Reactive oxygen species and synaptic plasticity in the aging hippocampus. Ageing Res Rev. 3: 431–43. PMID: 15541710
85. Sama MA, Mathis DM, Furman JL, Abdul HM, Artiushin IA, Kraner SD, et al. (2008) Interleukin-1betadependent signaling between astrocytes and neurons depends critically on astrocytic calcineurin/ NFAT activity. J Biol Chem. 283: 21953–64. PMID: 18541537 doi: 10.1074/jbc.M800148200
86. Szymocha R, Akaoka H, Dutuit M, Malcus C, Didier-Bazes M, Belin MF, et al. (2000) Human T-cell lymphotropic virus type 1-infected T lymphocytes impair catabolism and uptake of glutamate by astrocytes via Tax-1 and tumor necrosis factor alpha. J Virol. 74: 6433–41. PMID: 10864655
87. Kielian T. (2008) Glial connexins and gap junctions in CNS inflammation and disease. J Neurochem. 106: 1000–16. PMID: 18410504 doi: 10.1111/j.1471-4159.2008.05405.x